Rocket Science Health Secures U.S. Patent for Precision Intranasal Drug Delivery Technology
Key Insights
Rocket Science Health Corp. (search) has been awarded U.S. Patent No. 12,403,275 for its fluid dynamics methodology that enables precise drug delivery to specific subregions of the nasal cavity, including the olfactory region (search).
The patented technology produces a liquid stream rather than a traditional spray plume, allowing direct access to the central nervous system (search) while preserving the stability of fragile biologics (search) and lipid nanoparticles (search).
The innovation addresses limitations of conventional delivery methods for mental health (search) and neurodegenerative disorder treatments, offering needle-free, self-administered drug delivery for home and community settings.
Rocket Science Health Corp. (search), a Canadian drug delivery technology company, has been awarded U.S. Patent No. 12,403,275 by the United States Patent and Trademark Office for its fluid dynamics methodology supporting precision intranasal drug delivery. The patent represents a significant advancement in needle-free drug delivery systems, particularly for therapies targeting the central nervous system (search).
Novel Delivery Mechanism Targets Brain Access
The patent covers methods for delivering therapeutic compositions to defined subregions of the nasal cavity, including the olfactory region (search). From these regions, molecules can directly reach the central nervous system (search), or can enter systemic circulation or access the mucosal immune system without being broken down. These drug pathways are often not available to conventional syringes or spray devices.
Unlike oral medications, drugs delivered through the upper nasal cavity offer a unique access point to the brain and central nervous system (search) that can optimize the brain's exposure to drug therapies and potentially improve health outcomes across a range of medical treatments.
Technology Preserves Fragile Formulations
"Our technology enables accurate dosing while preserving the stability of fragile biologics (search), lipid nanoparticles (search), and higher-viscosity formulations through a patented low-force fluid ejection method," said Sohier Hall, President of Rocket Science Health. "Simply put, this technology produces a liquid stream and not a traditional spray plume."
The low-force fluid ejection method distinguishes the technology from traditional nasal spray devices, which may compromise the integrity of sensitive biological compounds. This capability is particularly relevant for modern drug development, where biologics (search) and complex formulations require gentle handling to maintain therapeutic efficacy.
Expanding Intellectual Property Portfolio
Together with previously issued device patents, Rocket Science Health now holds intellectual property that spans both the physical delivery system and the underlying methodology. Hall noted that "these innovations create opportunities for drug developers seeking precise dosing solutions and for patients who want needle-free delivery that can be easily self-administered at home or in community settings."
The company's technology supports development of therapies for mental health (search), neurodegenerative disorders (search), and other conditions where current routes of administration—such as intravenous injection or conventional nasal sprays—may offer limited efficacy or unwanted side effects.
Clinical Applications and Market Impact
The needle-free intranasal device enables non-clinical self-administration for at-home care, emergency rescue, and mass immunization scenarios. The fluidics are specifically engineered for today's delicate biologics (search) and dose-dependent drugs, addressing a critical need in pharmaceutical delivery systems.
Rocket Science Health's intellectual property portfolio is licensed to pharmaceutical partners to support both the advancement of new molecules and the optimization of existing drugs. The company, founded by Canadian business leader Kenneth Irving, focuses on creating innovations that expand access to care, particularly for under-resourced communities and individuals who face physical, cognitive, or challenging care environments where thoughtful design can improve health outcomes.